The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

被引：6

作者：

Kelley, R. ^{[1
]}

Kudo, M. ^{[2
]}

Harris, W. ^{[3
]}

Ikeda, M. ^{[4
]}

Okusaka, T. ^{[5
]}

Kang, Y. ^{[6
]}

Qin, S. ^{[7
]}

Tai, D. ^{[8
]}

Lim, H. ^{[9
]}

Yau, T. ^{[10
]}

Yong, W. ^{[11
]}

Cheng, A. ^{[12
]}

Gasbarrini, A. ^{[13
]}

de Braud, F. ^{[14
]}

Bruix, J. ^{[15
]}

Borad, M. ^{[16
]}

Standifer, N. ^{[17
]}

He, P. ^{[18
]}

Negro, A. ^{[18
]}

Vlahovic, G. ^{[18
]}

Sangro, B. ^{[19
,20
]}

Abou-Alfa, G. ^{[21
]}

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Kindai Univ, Fac Med, Osaka, Japan

[3] Univ Washington, Seattle, WA 98195 USA

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Natl Canc Ctr, Tokyo, Japan

[6] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[7] Jinling Hosp, PLA Canc Ctr, Nanjing, Peoples R China

[8] Natl Canc Ctr, Singapore, Singapore

[9] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[10] Univ Hong Kong, Hong Kong, Peoples R China

[11] Natl Univ Canc Inst Singapore, Singapore, Singapore

[12] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[13] Univ Cattolica Sacro Cuore, Milan, Italy

[14] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy

[15] BCLC Hosp Clin, Barcelona, Spain

[16] Mayo Clin Phoenix, Phoenix, AZ USA

[17] AstraZeneca, San Francisco, CA USA

[18] AstraZeneca, Gaithersburg, MD USA

[19] Clin Univ Navarra, Pamplona, Spain

[20] CIBEREHD, Pamplona, Spain

[21] Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.04.059

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-6

引用

页码：S233 / S234

页数：2

共 50 条

[1] Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
Kelley, Robin Kate
Sangro, Bruno
Harris, William Proctor
Ikeda, Masafumi
Okusaka, Takuji
Kang, Yoon-Koo
Qin, Shukui
Tai, Wai Meng David
Lim, Ho Yeong
Yau, Thomas
Yong, Wei-Peng
Cheng, Ann-Lii
Gasbarrini, Antonio
De Braud, Filippo G.
Bruix, Jordi
Borad, Mitesh J.
He, Philip
Negro, Alejandra
Kudo, Masatoshi
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Kelley, R. K.
Negro, A.
Chen, C.
Ali, S.
Standifer, N.
Watras, M.
Evans, B.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2020, 31 : S1429 - S1429
[3] COST-EFFECTIVENESS OF TREMELIMUMAB OR TREMELIMUMAB IN COMBINATION WITH DURVALUMAB VS DURVALUMAB AS TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
Tang, T.
Shi, L.
VALUE IN HEALTH, 2023, 26 (06) : S138 - S138
[4] Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Kudo, Masatoshi
LIVER CANCER, 2022, 11 (02) : 87 - 93
[5] Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
Kelly, Ronan Joseph
Lee, Jeeyun
Bang, Yung-Jue
Almhanna, Khaldoun
Murphy, Mariela A. Blum
Catenacci, Daniel V. T.
Chung, Hyun Cheol
Wainberg, Zev A.
Gibson, Michael
Lee, Keun Wook
Bendell, Johanna C.
Denlinger, Crystal S.
Brohawn, Philip Z.
He, Peng
McDevitt, Jennifer
Englert, Judson
Ku, Geoffrey Yuyat
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, Austin G.
Ulahannan, Susanna V.
Makorova-Rusher, Oxana
Rahma, Osama
Wedemeyer, Heiner
Pratt, Drew
Davis, Jeremy L.
Hughes, Marybeth S.
Heller, Theo
ElGindi, Mei
Uppala, Ashish
Korangy, Firouzeh
Kleiner, David E.
Figg, William D.
Venzon, David
Steinberg, Seth M.
Venkatesan, Aradhana M.
Krishnasamy, Venkatesh
Abi-Jaoudeh, Nadine
Levy, Elliot
Wood, Brad J.
Greten, Tim F.
JOURNAL OF HEPATOLOGY, 2017, 66 (03) : 545 - 551
[7] Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
Tomonari, Tetsu
Tani, Joji
Sato, Yasushi
Tanaka, Hironori
Morishita, Akihiro
Okamoto, Koichi
Kawano, Yutaka
Sogabe, Masahiro
Miyamoto, Hiroshi
Takayama, Tetsuji
JGH OPEN, 2024, 8 (10):
[8] Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
Wainberg, Zev A.
Segal, Neil Howard
Jaeger, Dirk
Lee, Kyung-Hun
Marshall, John
Antonia, Scott Joseph
Butler, Marcus
Sanborn, Rachel E.
Nemunaitis, John J.
Carlson, Cheryl Ann
Finn, Richard S.
Jin, Xiaoping
Antal, Joyce
Gupta, Ashok Kumar
Massard, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
Patel, Timil H.
Brewer, Jamie R.
Fan, Jiaxin
Cheng, Joyce
Shen, Yuan-Li
Xiang, Yue
Zhao, Hong
Lemery, Steven J.
Pazdur, Richard
Kluetz, Paul G.
Fashoyin-Aje, Lola A.
CLINICAL CANCER RESEARCH, 2024, 30 (02) : 269 - 273
[10] Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma
Chamseddine, Shadi
Lapelusa, Michael
Xiao, Lianchun
Mohamed, Yehia, I
Lee, Sunyoung S.
Hu, Zishuo Ian
Hatia, Rikita, I
Hassan, Manal
Yao, James C.
Duda, Dan G.
Datar, Saumil
Amin, Hesham M.
Kaseb, Ahmed
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 455 - 461

← 1 2 3 4 5 →